Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies

Roman Hovorka, Kavita Kumareswaran, Julie Harris, Janet M Allen, Daniela Elleri, Dongyuan Xing, Craig Kollman, Marianna Nodale, Helen R Murphy, David B Dunger, Stephanie A Amiel, Simon R Heller, Malgorzata E Wilinska and Mark L Evans
BMJ: British Medical Journal
Vol. 342, No. 7803 (23 April 2011), p. 906
Published by: BMJ
Stable URL: http://www.jstor.org/stable/41150309
Page Count: 1
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Preview not available

Abstract

STUDY QUESTION What is the safety and efficacy of overnight closed loop delivery of insulin (artificial pancreas) compared with conventional insulin pump therapy in adults with type 1 diabetes? SUMMARY ANSWER Closed loop delivery of insulin may significantly improve overnight glucose control and reduce the risk of nocturnal hypoglycaemia in adults with type 1 diabetes. The closed loop system has the potential to improve the safety and efficacy of overnight delivery of insulin. WHAT IS KNOWN AND WHATTHIS PAPER ADDS Overnight closed loop delivery of insulin improves control of plasma glucose levels in children and adolescents after large meals and exercise, but efficacy in adults is unknown. In these two small crossover trials overnight closed loop delivery of insulin in adults with type 1 diabetes improved glucose control and reduced exposure to low plasma glucose levels, with no overnight values below 3.0 mmol/L.

Page Thumbnails

  • Thumbnail: Page 
906
    906